Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

BACKGROUND: Challenges exist in the clinical treatment of luminal estrogen receptor α (ERα)-positive breast cancers (BCs) both to prevent resistance to endocrine therapy (ET) and to treat ET-resistant metastatic BCs (MBC). Therefore, we evaluated if kinases could be new targets for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pescatori, Sara, Leone, Stefano, Cipolletti, Manuela, Bartoloni, Stefania, di Masi, Alessandra, Acconcia, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006609/
https://www.ncbi.nlm.nih.gov/pubmed/35418303
http://dx.doi.org/10.1186/s13046-022-02360-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006609/
https://www.ncbi.nlm.nih.gov/pubmed/35418303
http://dx.doi.org/10.1186/s13046-022-02360-y

Ejemplares similares